Relmada Therapeutics (RLMD) Competitors $0.29 0.00 (-0.75%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.41%) As of 04/17/2025 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. KPTI, DTIL, ATRA, SPRO, CNTB, CELU, FBLG, INKT, SRZN, and KZRShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Karyopharm Therapeutics (KPTI), Precision BioSciences (DTIL), Atara Biotherapeutics (ATRA), Spero Therapeutics (SPRO), Connect Biopharma (CNTB), Celularity (CELU), FibroBiologics (FBLG), MiNK Therapeutics (INKT), Surrozen (SRZN), and Kezar Life Sciences (KZR). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Karyopharm Therapeutics Precision BioSciences Atara Biotherapeutics Spero Therapeutics Connect Biopharma Celularity FibroBiologics MiNK Therapeutics Surrozen Kezar Life Sciences Relmada Therapeutics (NASDAQ:RLMD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation. Does the MarketBeat Community believe in RLMD or KPTI? Karyopharm Therapeutics received 524 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 72.42% of users gave Karyopharm Therapeutics an outperform vote while only 37.78% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformRelmada TherapeuticsOutperform Votes1737.78% Underperform Votes2862.22% Karyopharm TherapeuticsOutperform Votes54172.42% Underperform Votes20627.58% Is RLMD or KPTI more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -52.62%. Karyopharm Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -129.80% -112.06% Karyopharm Therapeutics -52.62%N/A -39.58% Which has stronger valuation & earnings, RLMD or KPTI? Relmada Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$98.79M-$2.65-0.11Karyopharm Therapeutics$145.24M0.29-$143.10M-$15.29-0.32 Does the media favor RLMD or KPTI? In the previous week, Relmada Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for Relmada Therapeutics and 1 mentions for Karyopharm Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat Karyopharm Therapeutics' score of -0.50 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Relmada Therapeutics Neutral Karyopharm Therapeutics Negative Do insiders & institutionals believe in RLMD or KPTI? 45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by insiders. Comparatively, 2.8% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more risk and volatility, RLMD or KPTI? Relmada Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Karyopharm Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Do analysts rate RLMD or KPTI? Relmada Therapeutics presently has a consensus target price of $4.25, suggesting a potential upside of 1,366.53%. Karyopharm Therapeutics has a consensus target price of $57.50, suggesting a potential upside of 1,061.62%. Given Relmada Therapeutics' higher possible upside, equities analysts plainly believe Relmada Therapeutics is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryKaryopharm Therapeutics beats Relmada Therapeutics on 9 of the 17 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.62M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.106.8821.7317.77Price / SalesN/A231.02379.1697.65Price / CashN/A65.6738.2234.64Price / Book0.105.916.443.98Net Income-$98.79M$142.72M$3.21B$247.44M7 Day Performance-1.93%4.33%2.82%1.82%1 Month Performance-2.09%-12.80%-8.67%-6.98%1 Year Performance-93.26%-9.71%11.32%1.49% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics3.3364 of 5 stars$0.29-0.8%$4.25+1,366.5%-93.8%$9.62MN/A-0.1010KPTIKaryopharm Therapeutics3.1918 of 5 stars$4.04+4.7%$57.50+1,323.3%-76.1%$34.01M$145.24M-3.96380Short Interest ↑High Trading VolumeDTILPrecision BioSciences3.5425 of 5 stars$4.40-4.6%$37.67+756.1%-56.4%$33.75M$68.70M73.35200Short Interest ↑ATRAAtara Biotherapeutics3.9738 of 5 stars$5.73+2.5%$17.75+209.8%-65.5%$33.57M$128.94M-0.22330News CoverageSPROSpero Therapeutics4.1033 of 5 stars$0.60+3.1%$5.00+733.6%-49.7%$33.53M$27.40M8.57150CNTBConnect Biopharma3.1316 of 5 stars$0.60-4.7%$8.00+1,233.1%-52.3%$33.22M$24.12M0.00110Short Interest ↓Gap UpHigh Trading VolumeCELUCelularity0.227 of 5 stars$1.39+0.7%N/A-53.0%$33.09M$48.20M0.00220Gap DownFBLGFibroBiologics1.5587 of 5 stars$0.87-0.7%$13.00+1,394.4%-87.5%$32.83MN/A-2.5610INKTMiNK Therapeutics3.0833 of 5 stars$8.24-2.0%$37.50+355.1%-16.6%$32.68MN/A-2.1130Short Interest ↓Positive NewsGap DownSRZNSurrozen3.6062 of 5 stars$9.80-10.8%$38.50+292.9%+4.2%$31.85M$10.66M-0.4580Short Interest ↓Gap UpKZRKezar Life Sciences3.7504 of 5 stars$4.35+5.6%$39.50+808.0%-49.1%$31.78M$7M-0.3360 Related Companies and Tools Related Companies Karyopharm Therapeutics Alternatives Precision BioSciences Alternatives Atara Biotherapeutics Alternatives Spero Therapeutics Alternatives Connect Biopharma Alternatives Celularity Alternatives FibroBiologics Alternatives MiNK Therapeutics Alternatives Surrozen Alternatives Kezar Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThe Last Time Stocks Looked Like This, They Didn’t Move For 16 YearsThere is nothing the Federal Reserve can do to stop what's coming next for U.S. stocks. As you've seen your...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RLMD Stock Free RLMD Stock Alerts